首页> 外文期刊>Best practice & research:Clinical obstetrics & gynaecology >The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids
【24h】

The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids

机译:黄体酮受体调节剂ulipristal乙酸盐与子宫肌瘤的大硫代啶酸盐的历史和用途

获取原文
获取原文并翻译 | 示例
           

摘要

Progesterone receptor modulators (PRM) or selective progesterone receptor modulators have two remarkable effects in treated women. They considerably suppress endometrial bleeding by incompletely understood mechanisms, and when administered in women with symptomatic fibroids, they produce a significant and potentially long-term decrease in fibroid volume. The crucial advantage of this therapy lies with the absence of suppression of ovarian oestrogen secretion, which is in contrast to GnRH agonists. Long-term treatments have proven to be useful, especially in women approaching the menopausal transition. However, their use is associated with endometrial modiffcations called PRM-associated endometrial changes (PAECs). Although these abnormalities are now described as benign, the treatment is best administered in an intermittent manner where the PAECs rapidly disappear, while the beneficial effects on fibroid size and uterine bleeding are maintained or even improved in the long term. (C) 2016 Published by Elsevier Ltd.
机译:孕酮受体调节剂(PRM)或选择性孕激素受体调节剂在治疗妇女中具有两个显着作用。它们通过不完全理解的机制抑制子宫内膜出血,并且当患有症状肌瘤的妇女中,它们在纤维体积中产生显着且可能的长期减少。这种治疗的关键优势在于没有抑制卵巢雌激素分泌,这与GNRH激动剂相反。长期治疗已被证明是有用的,特别是在接近更年期过渡的女性中。然而,它们的用途与称为PRM相关的子宫内膜变化(PAEC)的子宫内膜瘤组相关联。尽管现在这些异常被描述为良性,但是最好的治疗是以间歇性的方式给药,其中PAECs迅速消失,而在长期保持甚至改善肌瘤大小和子宫出血的有益效果。 (c)2016由elestvier有限公司出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号